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Problem
Clostridium sordellii causes endometrial infections, but little is known
regarding host defenses against this pathogen.
Method of study
We tested the hypothesis that the immunoregulatory lipid prostaglandin
(PG) E2 suppresses human macrophage clearance of C. sordellii through
receptor-induced increases in intracellular cyclic adenosine monophos-
phate (cAMP). The THP-1 macrophage cell line was used to quantify
C. sordellii phagocytosis.
Results
PGE2 increased cAMP levels, activated protein kinase A (PKA), and
inhibited the class A scavenger receptor-dependent phagocytosis of
C. sordellii. Activation of the EP2 and EP4 receptors increased intracellu-
lar cAMP and inhibited phagocytosis, with evidence favoring a more
important role for EP4 over EP2. This was supported by EP receptor
expression data and the use of pharmacological receptor antagonists. In
addition, the PKA isoform RI appeared to be more important than RII in
mediating the suppression of ingestion of C. sordellii.
Conclusion
The endogenous lipid mediator PGE2 impairs human innate immune
responses against C. sordellii.
Introduction
Clostridium sordellii is an anaerobic Gram-positive
bacillus that is found in the environment and is an
uncommon cause of human infection. However,
infections caused by toxigenic strains of C. sordellii can
be severe due to the occurrence of a treatment-refrac-
tory toxic shock syndrome.1 Women of reproductive
age are at increased risk of C. sordellii infections
(including endometritis) that complicate childbirth,
abortion, and gynecological procedures.2 Despite
aggressive medical and surgical treatment, the
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mortality of C. sordellii infections has remained high.1
The development of better therapeutic options for
C. sordellii infection is limited by a lack of understand-
ing of fundamental host–microbial interactions
involved in the pathogenesis of infection.
Macrophages are important sentinels of innate
immunity in the soft tissues and have been impli-
cated as critical cellular participants in host defense
against tissue-invasive clostridial infection.3–5 It was
recently reported that macrophage phagocytosis of
vegetative C. sordellii was mediated by class A scav-
enger receptors, particularly the macrophage recep-
tor with collagenous structure (MARCO).6 It was
also demonstrated that misoprostol, a pharmacologi-
cal analog of E-series prostaglandins (PG), could
impair the phagocytosis of C. sordellii by rodent mac-
rophages.7 This suggested that immune surveillance
and clearance of C. sordellii were susceptible to nega-
tive regulation by endogenous PGs, which is poten-
tially important because the female reproductive
tract is replete with PGs during pregnancy.8,9
The compound PGE2 is an arachidonic acid-derived
lipid mediator generated in abundance at sites of
infection and inflammation as a result of the rapid
up-regulation of cyclooxygenase-2 and microsomal
PGE synthase-1 enzymes.10 It is also an important
hormonal regulator of reproduction that is generated
in the uterus where it is involved in early and late
processes ranging from implantation of the fertilized
egg to parturition.11 PGE2 is a highly potent modula-
tor of innate and adaptive immunity that influences
cell behavior through the ligation of its four distinct
G-protein-coupled E-prostanoid (EP) receptors, num-
bered EP1-4.12,13 Both EP2 and EP4 are potent
immunoregulatory receptors that share the capacity
to increase intracellular concentrations of cyclic
adenosine monophosphate (cAMP) within seconds to
minutes of PGE2 binding.
13,14 PGE2-dependent
increases in cAMP have been shown to impair the
phagocytic ability of different macrophage types
against a range of pathogens,15–18 and it can be sug-
gested that such effects might have evolved to limit
the extent of host inflammatory responses or trigger
the resolution of inflammation. However, in clinical
situations such as pregnancy and the puerperium,
where local and systemic PGE2 levels are elevated for
physiological reasons,19–21 the immunosuppressive
effects of PGE2 might be maladaptive, particularly
when an opportunistic pathogen such as C. sordellii
gains access to the normally uninfected uterus (or
surrounding soft tissue).
The purpose of this study was to address the ques-
tion of whether PGE2 and cAMP-signaling cascades
could regulate the phagocytosis of C. sordellii by
human macrophages and to determine the involve-
ment and relative importance of EP2 and EP4 recep-
tors in such regulation. A better understanding of
endogenous regulators of innate immunity will
enhance efforts to develop better preventive and ther-
apeutic options against reproductive tract infections.
Materials and methods
THP-1 Cells
Phorbol-12-myristate-13-acetate (PMA)-differentiated
THP-1 cells (a human macrophage-like cell line) were
used in this study. These cells were obtained from the
American Type Culture Collection (ATCC, TIB-202;
Manassas, VA, USA) and cultured in RPMI 1640
(Invitrogen, Carlsbad, CA, USA) supplemented with
1% antibiotic-antimycotic (Invitrogen) and 10%
charcoal-/dextran-treated fetal bovine serum (FBS;
HyClone, Waltham, MA, USA), referred to as RPMI
+/+. Cells were passaged every 2–4 days and were used
through the 10th passage, at which time a new culture
was started. THP-1 cells were matured into macrophag-
es by culturing with 100 nM PMA (Sigma-Aldrich, St.
Louis, MO, USA) in RPMI +/+ for 24 hr at 37°C with
5% CO2. Cells were detached from the flask with non-
enzymatic cell dissociation solution (Sigma-Aldrich)
and gentle scraping. Phorbol-12-myristate-13-acetate-
activated THP-1 cells were used for all experiments pre-
sented here, unless otherwise noted.
Bacteria
The lethal toxin–expressing C. sordellii strain 9714
was obtained from the ATCC and grown anaerobi-
cally for 48 hr at 37°C in reinforced clostridial
medium (RCM; BD Biosciences, San Jose, CA, USA).
Bacterial concentrations were estimated from the
optical density (OD) of bacterial cultures at 600 nm
(OD600) and a standard curve of colony-forming
units (CFU) versus OD600. Estimated bacterial con-
centrations were confirmed by serial 10-fold dilu-
tions on solid RCM containing 1.5% agar and
incubated overnight anaerobically. For phagocytosis
experiments (below), heat-killed, vegetative C. sordel-
lii were prepared by incubating at 65°C for 2 hr.
Spore contamination was estimated by Schaeffer and
Fulton Spore Stain (Sigma-Aldrich) to be <10%.
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Heat-killed C. sordellii were then surfaced-labeled
with either FITC, per our previously published pro-
tocol,7 or [C15H16N3]
+[Zn8S(SC6H5)15
.H2O]
 (abbr.
JX90a) as previously published.22 Although qualita-
tive results using either fluorophore were similar,
the fluorescent labeling was brighter with JX90a.
Therefore, it was used for many of the experiments
in preference to FITC. Briefly, heat-killed C. sordellii
were labeled overnight in NaHCO3 buffer (pH 9.2)
with 100 lL of the bacterial dye JX90a. Bacteria
were washed with PBS by centrifugation and stored
at 80°C in single-use aliquots until each phagocy-
tosis assay was performed. Herein, we refer to fluor-
escently labeled C. sordellii (using either FITC or
JX90a) as FLUORC. sordellii.
Phagocytosis Assays
Phorbol-12-myristate-13-acetate-activated THP-1
cells were treated in RPMI +/ (lacking FBS) with
compounds of interest and incubated for 15 or 30 min
at 37°C as indicated, on 384-well tissue-culture-trea-
ted plates. All conditions were performed in replicates
of eight. Cells were inoculated with FITC- or JX90a-
labeled C. sordellii (FLUORC.sordellii) at a multiple of
infection (MOI) of 300 bacteria:1 cell and incubated
for 3 hr at 37°C. Phagocytosis was quantified accord-
ing to our published method of measuring intracellu-
lar fluorescence as a surrogate marker of bacterial
ingestion by macrophages.15 The fluorescence of
intracellular FLUORC.sordellii was determined using a
microplate fluorometer (485ex/535em FITC; 470ex/
500em JX90a, SPECTRAMax GEMINI EM; Molecular
Devices, Sunnyvale, CA, USA) according to our previ-
ously published method.15 Briefly, fluorescence was
expressed in relative fluorescence units (RFU), which
were converted into a phagocytic index (PI). The PI
represents the fluorescence of intracellular (phagocy-
tosed) bacteria (RFUi) and was calculated from the
total fluorescence of the well (RFUtotal) by subtracting
the fluorescence of extracellular bacteria (RFUex). The
RFUex was determined by treating some cells with the
phagocytosis inhibitor, cytochalasin D (20 lg/mL;
EMD Chemicals, Billerica, MA, USA), for 30 min
prior to exposure to FLUORC.sordellii.23 The mean
RFUex determined from cytochalasin-treated wells
was then subtracted from the RFUtotal. Therefore, the
PI = RFUi = RFUtotalRFUex.15
Treatments used in our phagocytosis assay included
the phagocytosis inhibitor, cytochalasin D (30 min,
20 lg/mL); prostaglandin E2 (PGE2; 15 min, 0.1, 1 lM;
Cayman Chemicals, Ann Arbor, MI, USA); cAMP ana-
logs adenosine 3′, 5′-cyclic monophosphate 8-bromo-
sodium salt (8-Bromo-cAMP; dual activator of protein
kinase A (PKA) and exchange protein directly activated
by cAMP (Epac-1)), adenosine 3′,5′-cyclic mono-
phosphate N6–benzoyl sodium salt (6-Bnz-cAMP;
PKA-specific), and adenosine 3′-5′-cyclic monophos-
phate 8-(4-chlorophenylthio)-2′-O-methyl sodium salt
(8-pCPT-cAMP; Epac-1-specific) (each 30 min, 0.1,
0.2, 1, 2 mM; EMD Chemicals); the EP2 agonist buta-
prost free acid (BFA; 15 min, 1, 10 lM; Cayman Chem-
icals); the EP4 agonist L-902,688 (15 min, 1, 10 lM;
Cayman Chemicals); the EP2 antagonist AH6809
(15 min, 1 lM; Cayman Chemicals); the EP4 antago-
nist ONO-AE1-208 (15 min, 1 lM; gift from the Ono
Pharmaceutical company in Osaka, Japan); the non-
selective class A scavenger receptor antagonists fucoi-
dan (30 min, 1 mg/mL; Sigma-Aldrich) and dextran
sulfate (30 min, 0.2 mg/mL; MP Biomedicals, Solon,
OH, USA); and the negative control agent chondroitin
sulfate (30 min, 0.2 mg/mL; Sigma-Aldrich); the PKA
RI agonist 2-Cl-8-MA-cAMP and the PKA RII agonist
6-MBC-cAMP (both 30 min, 500 lM; Axxora, Farm-
ingdale, NY, USA).
Measurement of Intracellular cAMP
Phorbol-12-myristate-13-acetate-activated THP-1 cells
were cultured in 6-well tissue-culture-treated plates
at a concentration of 3 x 106 cells/well in RPMI +/.
Cells were incubated with PGE2, BFA, L-902,688,
AH6809, or ONO-AE1-208 (1 or 10 lM) for 15 min.
Culture supernatants were removed, and cells were
lysed by incubation with 0.1 M HCl for 10 min at
room temperature followed by gentle scraping.
Lysates were harvested by centrifugation and stored at
80°C. Intracellular cAMP levels were measured by
EIA according to the manufacturer (Enzo/Assay
Designs, Ann Arbor, MI, USA), and all samples were
assayed in triplicate.
Measurement of PKA Activation
The activation of PKA was assessed by quantitative
immunoblot of the PKA phosphorylation target vaso-
dilator-stimulated phosphoprotein (VASP).24,25 THP-
1 cells were PMA-activated for 48 hr followed by an
overnight rest period in RPMI +/+. Phorbol-12-myri-
state-13-acetate-activated THP-1 cells were then
treated for 15 min with 1 lM PGE2 in 100-mm
2
tissue-culture-treated dishes before lysis in Lysis
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Buffer #6 (R&D Systems, Minneapolis, MN, USA).
Protein samples (40 lg) were resolved on 10% Tris–
HCl polyacrylamide gels and transferred to a nitrocel-
lulose membrane. Membranes were probed with
phospho-(Ser157) VASP rabbit antibody (Cell Signal-
ing Technology, Danvers, MA, USA), followed by HRP-
conjugated anti-rabbit secondary antibody and Pierce
ECL detection reagents (Thermo Scientific, Rockford,
IL, USA). Quantification of the phospho-target was
normalized to the housekeeping protein a-tubulin.
Immunoblot Analysis of EP2 and EP4 Receptors
Non-PMA-treated THP-1 cells in suspension were cen-
trifuged and lysed in Lysis Buffer #6. Protein samples
(40 lg) were resolved on 10% Tris–HCl polyacryl-
amide gels and transferred to a nitrocellulose mem-
brane. Membranes were probed with the EP2 and EP4
receptor polyclonal antibodies (Cayman Chemicals),
followed by HRP-conjugated anti-rabbit secondary
antibody and Pierce ECL detection reagents. Quantifi-
cation of each receptor was normalized to the
housekeeping protein a-tubulin.
Quantitative Real-Time PCR Analysis
Phorbol-12-myristate-13-acetate-activated THP-1 cells
were stored in TRIzol Reagent (Invitrogen) at 80°C
until RNA was extracted and cDNA was generated per
our previously published protocol.6 Human primers
and probes were designed using the Roche Universal
Probe Library Assay Design Center. Primers were gen-
erated by Integrated DNA Technology and all probes
were from Roche (Basel, Switzerland). Primers used
are as follows: human EP2 forward 5′-GGA GGA GAC
GGA CCA CCT-3′, EP2 reverse 5′- GTT TCA TTC ATA
TAT GCA AAA ATC GT-3′ (Universal Probe Library
#2); and human EP4 forward 5′-CTC CCT GGT GGT
GCT CAT-3′, EP4 reverse 5′-GGC TGA TAT AAC TGG
TTG ACG A-3′ (Universal Probe Library # 58). The
Universal Probe Library Gene Assay (Roche) for
human GAPDH was also used (Universal Probe
Library # 60). Samples were run on the Light Cycler
480 (Roche) with the following conditions: 95°C,
10 min (pre-incubation); 95°C 10 s; 60°C, 30 s; 72°C,
1 s (amplification, 45 cycles); 95°C, 10 s; 50°C, 30 s;
70°C, 5 min (melting curve); 40°C, 30 s (cooling).
Analysis was performed using the Roche software,
and expression of each gene was referenced to the
expression of the housekeeping gene GAPDH. Results
were calculated using the 2DDCT method.
26
Statistical Analyses
Statistical analyses were carried out using GraphPad
Prism 5.0 software for Windows (GraphPad Software,
San Diego, CA, USA). Unless otherwise stated, experi-
mental data are presented as a percentage of the
untreated control group (set at 100%). Error bars rep-
resent the standard error of the mean (S.E.M.). All
analyses were conducted on raw data prior to normal-
izing to the untreated control. Where appropriate,
mean values were compared using a paired Student’s
t-test or a repeated measured analysis of variance (ANO-
VA). A Dunnett’s post-test was conducted for compari-
sons with the control value, or a Tukey’s test was
performed for multiple comparisons. Differences were
considered significant if P ≤ 0.05. Experiments were
performed on at least three separate occasions.
Results
Prostaglandin E2 Inhibits the Class A Scavenger
Receptor-Dependent Phagocytosis of Unopsonized
C. sordellii by THP-1 cells
The PGE1 analog misoprostol, which binds to the
same four EP receptors as does PGE2,
27 was previously
found to inhibit the phagocytosis of vegetative C. sord-
ellii by rodent macrophages.7 The capacity for authen-
tic PGE2 to regulate human phagocyte–clostridial
interactions has not been examined. Human THP-1
macrophage-like cells were used to model the regula-
tion of phagocytosis of unopsonized, vegetative
C. sordellii. Although C. sordellii phagocytosis has been
shown to be mediated by class A scavenger receptors
(CASRs) in rodent macrophages and human decidual
macrophages,6 the dependence on CASRs for inter-
nalization of C. sordellii by THP-1 cells was unknown.
Therefore, initial experiments were performed with
the CASR-blocking compound fucoidan (1 mg/mL),
which almost completely prevented the phagocytosis
of FLOURC. sordellii by THP-1 cells (P < 0.001), con-
firming the importance of CASRs in this process
(Fig. 1a). Additionally, when cells were treated with
the standard, non-selective CASR-blocking agent dex-
tran sulfate at 0.2 mg/mL, there was an inhibition of
81.6  3.5% of phagocytic activity (P < 0.001), while
the negative control agent chondroitin sulfate had a
minimal effect at the same dose (Fig. 1a). Exposure of
THP-1 cells to exogenously added PGE2 (0.1 or 1 lM)
dose-dependently inhibited the phagocytosis of
unopsonized FLUORC. sordellii (Fig. 1b), with an
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inhibition of 35  12.7% (P < 0.05) and
54.7  14.5% (P < 0.01), respectively.
Activation of EP2 and EP4 Receptors by PGE2
Increases cAMP in THP-1 Cells and this Effect is
Blocked with an EP4 Antagonist
The Gas-coupled EP2 and EP4 receptors are important
immunoregulatory receptors on macrophages,15,28–30
and THP-1 cells have been reported to express both
EP2 and EP4 receptors.31 We therefore verified that
PGE2 could increase cAMP in THP-1 cells, finding a
20  3.7-fold increase (P < 0.0001) with 1 lM PGE2
(Fig. 1c). That both EP2 and EP4 receptors were
active in these cells was supported by an increase in
cAMP observed when cells were incubated for 15 min
with the selective EP2 or EP4 agonists BFA or
L-902,688, respectively (Fig. 2a). The activation of
the EP2 receptor evoked 1.8-fold and 3.3-fold
increases in cAMP with BFA (1 and 10 ll, respec-
tively), while EP4 stimulation with L-902,688
induced 7.1-fold (P < 0.001) and 5.7-fold (P < 0.05)
increases in cAMP (1, 10 ll, respectively). To further
explore EP2 and EP4 activation on THP-1 cell phago-
cytosis, cells were pre-treated with L-902,688 or BFA
for 15 min. It was found that L-902,688 (EP4 agonist)
exposure suppressed the capacity of THP-1 cells to
ingest unopsonized FLUORC. sordellii, while BFA was
effective but not quite as potent (Fig. 2b). EP2 and
EP4 antagonists were used to define the extent to
which these receptors mediate the actions of PGE2 on
THP-1 cells. As indicated in Fig. 2c, cAMP increases
provoked by PGE2 were blocked by the EP4 antago-
nist ONO-AE1-208 but not by the EP2/DP1 antago-
nist AH6809 (1 lM each).
EP4 Receptors are Expressed in Greater
Abundance than EP2 Receptors by THP-1 Cells
To confirm EP2 and EP4 receptor expression by THP-1
cells, cells were lysed and subjected to immunoblot
analysis for the detection of these receptors. A band at
the expected molecular weight of ~52 kDa was observed
for the EP2 receptor, but as evidenced in Fig. 2d, several
larger bands were also detected, which are of uncertain
significance. A single band at the expected 65 kDa was
detected for EP4 (Fig. 2e). Because the EP2 immunoblot
result was inconclusive, experiments were conducted to
determine mRNA expression levels of EP2 and EP4
using quantitative real-time PCR. RNA was isolated,
cDNA was reverse transcribed, and real-time PCR was
performed for EP2 and EP4. We found significantly
higher expression of EP4 compared with EP2 by THP-1
cells (P < 0.01) (Fig. 2f).
PKA Activation Inhibits C. sordellii Phagocytosis
Once cAMP is generated in a macrophage, it can acti-
vate downstream signaling cascades by binding to
effector proteins such as the Ser/Thr phosphorylating
enzyme called PKA or the guanine-nucleotide
exchange protein directly activated by cAMP (Epac-
1).32 Experiments were conducted to determine
whether cAMP itself could regulate phagocytosis of
C. sordellii and, if so, through which effector proteins.
Thus, cells were pre-treated with the dual (non-selec-
tive) PKA/Epac-1 activator and cAMP analog 8-Br-
cAMP, which significantly reduced phagocytosis by
38.2  7.4% (P < 0.01) at a concentration of 1 mM
(data not shown). To determine whether the activa-
tion of either PKA or Epac-1 (or both) mediated the
(a) (b) (c)
Fig. 1 Prostaglandin E2 inhibits class A scavenger receptor–dependent phagocytosis of unopsonized C. sordellii by THP-1 cells. Cells were treated
with the class A scavenger receptor antagonists (a) fucoidan, dextran sulfate, or the structurally similar negative control chondroitin sulfate for
30 min (n = 3-4), or (b) PGE2 (n = 6) for 15 min prior to challenge with
FLUORC. sordellii as described in Materials and Methods. Phagocytosis was
quantified by fluorometry. Data are mean  S.E.M. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by ANOVA. (c) Cells were treated with PGE2 for 15 min
before lysis with 0.1 M HCl and cyclic adenosine monophosphate measurement by EIA (n = 12). Data are mean  S.E.M. ****, P < 0.0001 by
Student’s paired t-test compared with untreated controls.
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actions of cAMP on this process, cells were pre-trea-
ted with the PKA or Epac-1-selective agonist’s 6-Bnz-
cAMP or 8-pCPT-2′-O-Me-cAMP, respectively. As
illustrated (Fig. 3a,b), only PKA activation resulted in
suppression of phagocytosis.
PKA is Activated by PGE2 as seen by
Phosphorylation of VASP
The data above demonstrate that PGE2 both inhib-
ited C. sordellii phagocytosis and enhanced cAMP in
THP-1 macrophages, while the cAMP-dependent
activation of PKA was sufficient to suppress phago-
cytosis. To determine whether PGE2 treatment can
directly activate PKA, we measured the phosphoryla-
tion of a canonical protein target of PKA in response
to treatment of cells with PGE2. VASP is a member
of the Ena-VASP protein family that is phosphory-
lated by PKA and is a robust surrogate for that
activity.24,25 THP-1 cells were exposed for 15 min
with 1 lM PGE2, and immunoblot analysis was per-
formed for phospho-VASP (Fig. 3c). As noted, PGE2
treatment resulted in an 11.2-fold (P < 0.05)
increase in phosphorylation of VASP when
compared with untreated control.
Activation of PKA Isozyme Type I, not Type II,
Counter-Regulates C. sordellii Phagocytosis
The cAMP-dependent PKA exists in two major iso-
forms, defined by their regulatory (cAMP-binding)
subunits: types RI and RII.33 Emerging data suggest
(a)
(c)
(d) (e) (f)
(b)
Fig. 2 EP2 and EP4 receptors mediate PGE2-
induced intracellular cyclic adenosine
monophosphate (cAMP increase and
phagocytosis inhibition in THP-1 cells. Cells
were treated for 15 min with (a) the EP2
agonist butaprost free acid (BFA) or the EP4
agonist L-902,688 (n = 3–5). Cells were lysed
and cAMP was measured by EIA. (b) Cells
were treated for 15 min with BFA or
L-902,688 followed by a challenge with
FLUORC. sordellii (n = 4). Phagocytosis was
quantified by fluorometry. (c) Cells were
pre-treated for 15 min with either the EP2
antagonist (AH6809) or the EP4 antagonist
(ONO-AE1-208), then PGE2 was administered
for an additional 15 min (n = 3), cells were
lysed, and cAMP was measured by EIA. Data
in (a–c) are represented as mean  S.E.M.
*, P < 0.05; **, P < 0.01; ****, P < 0.0001
by ANOVA compared with the untreated
control. Cells were lysed and immunoblot
analysis was performed for (d) EP2 and (e)
EP4 receptors (n = 5 each; representative
immunoblots). (f) qRT-PCR was performed for
EP2 and EP4 on THP-1 cells (n = 3). Data are
represented as mean  S.E.M. of fold
regulation. **, P < 0.01 by unpaired
Student’s t-test comparing EP2 to EP4.
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that cellular functions in macrophages are governed
by distinct isoforms.34 We examined the capacity for
type RI and RII agonists (2-Cl-8-MA-cAMP and
6-MBC-cAMP, respectively) to regulate phagocytosis
of C. sordellii and found that the activation of PKA
type RI resulted in an inhibition of 33.8  9.4%
(P < 0.01), while PKA type RII only inhibited phago-
cytosis by 7.2  4.8% (Fig. 3d).
Discussion
Globally, more than 500,000 women die from compli-
cations of pregnancy and childbirth each year,35 and
nearly 1 in 8 maternal deaths is due to unsafe abor-
tion.36,37 Sepsis is a principal cause of maternal death
after childbirth38 or abortion.37 Pregnancy itself is
associated with major shifts in immune surveillance39
as the maternal immune system must be ‘detuned’ to
accommodate the immunologically distinct fetus.40
Despite this, a mother’s immune system must be able
to detect and respond to potentially pathogenic
organisms. However, some pathogens have evolved
mechanisms to evade host defense, apparently taking
advantage of the immunological shifts associated with
pregnancy. For example, certain Gram-positive bacte-
ria are adept at causing pregnancy-related infections,
including Listeria monocytogenes, Streptococcus pneumo-
niae, Group A Streptococcus, Group B Streptococcus, and
the clostridia.41–43 Clostridium sordellii infections have
increasingly been observed over the past decade in
healthy women of reproductive age following child-
birth or abortion.2 In addition to C. sordellii, there is
an unexplained association between C. difficile colitis
and both pregnant and postpartum women.44,45 The
basis for the enhanced susceptibility of postpartum
women to infection remains to be solved.
Major gaps in our understanding of immune sur-
veillance and host defense against clostridial infec-
tions are apparent, in part because the field is
understudied. Recent work in this area has focused
on C. difficile and C. perfringens but has not explored
reproductive tract immune defenses.3,5,46,47 Macro-
phages are important in defending the host against
invasive clostridial infections such as C. perfringens3,48
and are adept at recognizing clostridia as either
spores or vegetative bacteria and targeting them for
immune clearance.5,6,49 Better understanding the
host factors that regulate macrophage–clostridial
interactions may reveal how such pathogens evade
host defenses to establish infection.
Our experiments newly establish that macrophage
phagocytosis of C. sordellii is subject to immunoregula-
tion by the immunomodulatory lipid mediator PGE2.
In the human THP-1 macrophage cell line, this effect
appeared to be primarily mediated by the EP4 recep-
tor with additional involvement of the EP2 receptor.
(a) (b)
(c) (d)
Fig. 3 The PGE2-mediated inhibition of
phagocytosis seen in THP-1 cells is PKA
dependent and not Epac-1 dependent. Cells
were treated for 30 min with (a) 6-Bnz-cAMP,
a PKA-dependent cAMP analog (n = 3) or
(b) 8-pCPT-cAMP, an Epac-1-dependent cAMP
analog (n = 3), or (d) the PKA RI agonist
2-Cl-8-MA-cAMP or the PKA RII agonist
6-MBC-cAMP for 30 min (n = 5), followed by
a challenge with FLUORC. sordellii.
Phagocytosis was quantified by fluorometry.
Data in a, b, and d panels are represented as
mean  S.E.M. **, P < 0.01 by a one-way
ANOVA with a Dunnett’s multiple comparison
test compared with untreated control.
(c) Cells were treated with 1 lM PGE2 for
15 min and lysed, and immunoblot analysis
was performed for phospho-VASP, a marker
of PKA activation (n = 5). Data are shown as
mean  S.E.M. *, P < 0.05 by a paired
Wilcoxon matched-pairs signed rank test.
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The evidence that EP4 might be more important than
EP2 was based on pharmacological stimulation and/or
antagonism of these receptors, as well as mRNA and
Western immunoblot data. The latter immunoblot
experiments identified a clear band of the appropriate
size for the EP4 receptor, but the EP2 antibody data
were less conclusive. Further studies using receptor
silencing or genetic knockout animals could provide
additional evidence for the relative importance of
these receptor isoforms in mediating PGE2’s actions.
Activation of adenylate cyclase by these receptors
caused an acute burst of intracellular cAMP that acti-
vated the canonical target PKA. Further studies impli-
cated the RI isoform of PKA as a regulatory signaling
component governing PGE2/cAMP modulation of
C. sordellii phagocytosis (summarized in Fig. 4). A key
unanswered question requiring future study is how
PKA activation reduces CASR-dependent phagocyto-
sis. It has been reported that PGE2 suppresses macro-
phage expression of the class B scavenger receptor
CD36,50,51 suggesting that CASR expression might be
similarly reduced. However, the effects of PGE2 on
phagocytosis are rapid (within 15 min of exposure),
which would support actions unrelated to new pro-
tein expression.
Our findings may have relevance to the pathogen-
esis of puerperal infections in addition to those
caused by clostridia. Throughout gestation, PGE2
dampens maternal immune responses against fetal
tissues.52–55 At term, systemic and local PGE2 levels
increase dramatically19,21 to induce cervical softening
and uterine smooth muscle contraction that aids in
delivery.9 It is this spike in PGE2 production at term
that may pose a risk for puerperal sepsis. Relevant to
this paradigm, a stable PGE2 analog delivered into
the maternal cervix postpartum in cows increased
the incidence of puerperal endometritis,56 while a
mouse study reported that PGE2 facilitated the estab-
lishment of chlamydial uterine infections.57 Thus,
high PGE2 levels in the female reproductive tract at
parturition might increase susceptibility to puerperal
infection.
These investigations were limited by their in vitro
design. Studies in women or animal models will be
important to determine the extent to which PGE2
regulates clostridial pathogenesis in vivo. Preliminary
experiments in our laboratory revealed increased
mortality in mice exposed to PGE2 in utero during
C. sordellii spore infection (data not shown), and this
is a future direction for our laboratory. What is
more, our work was largely conducted using a cell
line. While the THP-1 cell is a standard human
macrophage-like cell line,58 these cells may not be
an accurate model of primary reproductive tract
macrophages. They were originally isolated from a
child with leukemia.59 We have previously found
that THP-1 cells behave similarly to primary placen-
tal macrophages in their capacity to phagocytose S.
pyogenes and to be regulated by lipid mediators.60
Thus, understanding the mechanisms whereby PGE2
regulates THP-1-C.sordellii interactions may be rele-
vant to reproductive tract innate immunity.
Another limitation of our work was the use of
heat-killed bacteria. While advantageous for study-
ing bacteria–receptor interactions without the con-
founding effects of bacterial products on host cell
function, such effects might be relevant in vivo.
Clostridium sordellii produces cytotoxins that could
regulate macrophage function. Future studies will be
needed to determine the extent to which C. sordellii
toxins impact macrophage antibacterial defense
functions. Lastly, we conducted these studies using
Fig. 4 A conceptual model of PGE2 inhibition of vegetative C. sordellii
phagocytosis by THP-1 cells. Vegetative C. sordellii bacteria are
phagocytosed via class A scavenger receptors (CASR). PGE2 stimulated
intracellular cAMP synthesis by adenylate cyclase (AC) following ligation
of the Gas-coupled EP2 and EP4 receptors. The cAMP burst in turn
activated the type I isoform of protein kinase A (PKA RI), which is
involved in suppressing the internalization of C. sordellii.
Pharmacological tools used in these experiments include the EP2
agonist butaprost free acid (BFA), the EP2 agonist L-902,
688, the EP2 antagonist AH-6809, the EP4 antagonists ONO AE1-208,
and the PKA RI agonist 2-Cl-8-MA-cAMP.
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vegetative forms of C. sordellii. As a spore-forming
anaerobe, it may be equally relevant to define how
macrophages recognize and attempt to clear spores
of C. sordellii from the infected host. Future studies
will be needed to address this issue.
In summary, these data reveal that the endoge-
nous lipid molecule PGE2 can limit the capacity for
THP-1 cells to phagocytose unopsonized C. sordellii,
and this occurs primarily via EP4-mediated activa-
tion of PKA signaling cascades. New preventive and
therapeutic strategies against this and other repro-
ductive tract bacterial infections may be identified
by studying eicosanoid immunoregulation of
immune defenses in the uterus.
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